For the Inventor, By the Inventor

Enter assignee name

Barcelona, Spain

Almirall, S.a.

USPTO Granted Patents = 57

% Expired Patents = 73.7

CIPO Patents = 5

EPO Patents = 56

Trademarks = 18

Forward Citations = 199

Loading Chart...

Loading Chart...

91 inventors (with patents filed for the assignee):

Maria Prat Quinones (16 out of 22 patents)

Carlos Puig Duran (16 out of 19 patents)

Maria Antonia Buil Albero (11 out of 23 patents)

4. Maria Dolors Fernandez Forner (10 out of 20 patents)

5. Jose Aiguade Bosch (8 out of 9 patents)

6. Silvia Gual Roig (7 out of 8 patents)

7. Silvia Fonquerna Pou (6 out of 11 patents)

8. Paul Robert Eastwood (6 out of 12 patents)

9. Jacob Gonzalez Rodriguez (5 out of 6 patents)

10. Maria Prat Quiñones (5 out of 13 patents)

11. Francesc Carrera Carrera (5 out of 5 patents)

12. Enrique Moyes Valls (5 out of 5 patents)

13. Gonzalo De Miquel Serra (4 out of 4 patents)

14. Joan Taltavull Moll (4 out of 5 patents)

15. Victor Giulio Matassa (4 out of 4 patents)

Core Competencies:

Pharmaceutical Compositions

JAK Inhibitors

Sodium Channel Inhibitors

Adrenergic Agonists

Quinuclidine Derivatives

Cyclohexylamine Derivatives

P38 Mitogen-Activated Kinase Inhibitors

Topical Formulations

Dosage Forms

Combination Therapies

Inhalation Devices

Powdered Pharmaceuticals

57 patents: Sort by Forward Citations

1. 11602515 - Pharmaceutical compositions comprising dimethyl fumarate (2023-03-14),

2. 11000517 - Dosage and formulation (2021-05-11),

3. 10759793 - 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors (2020-09-01),

4. 10588895 - Quinuclidine derivatives and medicinal compositions containing the same (2020-03-17),

5. 10456390 - Combinations comprising MABA compounds and corticosteroids (2019-10-29),

6. 10300072 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2019-05-28),

7. 10214509 - Amino-substituted heterocyclic derivatives as sodium channel inhibitors (2019-02-26),

8. 10173985 - Aminoindazole derivatives as sodium channel inhibitors (2019-01-08),

9. 10085974 - Dosage and formulation (2018-10-02),

10. 10034867 - Quinuclidine derivatives and medicinal compositions containing the same (2018-07-31),

11. 10005771 - Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2018-06-26),

12. 9907807 - Topical pharmaceutical compositions (2018-03-06),

13. 9757383 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2017-09-12),

14. 9737520 - Aclidinium for use in improving the quality of sleep in respiratory patients (2017-08-22),

15. 9687478 - Quinuclidine derivatives and medicinal compositions containing the same (2017-06-27),

Company Overview

Almirall, S.A., headquartered in Barcelona, Spain, is a prominent player in the pharmaceutical industry, focusing on the development and commercialization of innovative therapeutic solutions. The company specializes in pharmaceutical compositions, with a strong emphasis on areas such as JAK inhibitors, sodium channel inhibitors, and adrenergic agonists. Almirall's research efforts are directed towards advancing treatments in dermatology and other therapeutic areas, leveraging its expertise in topical formulations and various chemical derivatives to address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

57 Patents

#7 in Barcelona

#19 in Spain

#12,552 in the World

Barcelona, Spain

Almirall, S.a.

Forward Citations = 199

91 inventors:

Maria Prat Quinones (16 out of 22 patents)

Carlos Puig Duran (16 out of 19 patents)

Maria Antonia Buil Albero (11 out of 23 patents)

4. Maria Dolors Fernandez Forner (10 out of 20 patents)

5. Jose Aiguade Bosch (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Almirall, S.a.. Retrieved from https://idiyas.com/company/almirall-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…